BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Int J Cancer
; 139(4): 882-9, 2016 Aug 15.
Article
in En
| MEDLINE
| ID: mdl-26946057
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
BRCA1 Protein
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Int J Cancer
Year:
2016
Type:
Article
Affiliation country:
Netherlands